Buenos Aires, April 12 (NA) -- The dengue vaccine has been approved in Argentina for ages 4 and up. However, to date, there are no specific studies that evaluate the safety and immune response in people over 60 years of age. In this situation, the Huésped Foundation has initiated a research study that seeks to generate scientific evidence on the tolerability and immune response to the dengue vaccine in people aged 60 to 79, according to a report accessed by the Argentine News Agency. To participate, people aged 60 to 79 who live in the City of Buenos Aires or the Buenos Aires Metropolitan Area (AMBA) with pre-existing health conditions, such as hypertension, diabetes, or kidney failure, may apply. Meanwhile, immunosuppressed individuals cannot participate, as it is a live attenuated virus vaccine, and those interested must complete a form where a series of data will be requested. The vaccine being researched is the one developed by the Japanese laboratory Takeda, which is currently the only dengue vaccine approved and used in Argentina. "It is the same vaccine that is applied in the country's vaccination centers, but the difference is that, to date, it has not been specifically evaluated in adults over 60 years of age," explained Florencia Cahn, director of the Vaccines Division of the Huésped Foundation. The specialist also added: "That is why this study is fundamental to provide data that allows us to better understand how the immune system responds to the vaccine in these age groups".
